U.S. Markets closed

Jefferies still expects positive FDA panel vote for Amarin

Following the FDA briefing documents released on Friday, Jefferies continues to expect a positive panel vote on October 16 for Amarin's Vascepa. However, the firm points out that 8 of the 10 panelists for Wednesday's meeting are new, making an outcome difficult to call. Jefferies has a Buy rating on Amarin with a $20 price target.